Inside informationEnglish
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 09/01/2025, 07:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 112178_20250109